ObsEva SA
DelistedCIK 1685316fmd_1NMVXD5RSSJZAXV7A23WR4244HManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2022, 12 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 0 | 0 | 0 | 22 | 20 |
| Net interest income | – | – | – | – | – | – | (3) | (9) |
| Research and development | 17 | 24 | 55 | 63 | 88 | 68 | 54 | 11 |
| Selling, general and administrative | 3 | 6 | 13 | 14 | 19 | 12 | 21 | – |
| Operating income | (20) | (30) | (67) | (77) | (107) | (80) | (57) | (16) |
| Interest expense | 0 | 0 | 0 | – | 2 | 4 | 4 | – |
| Other non-operating income (expense) | – | – | – | – | – | – | 4 | (14) |
| Income before taxes | (20) | (67) | (67) | (77) | (109) | (83) | (53) | (30) |
| Income tax expense | – | – | 0 | (0) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | (67) | (77) | (109) | (83) | (53) | (30) |
| Net income | (20) | (30) | (67) | (77) | (109) | (83) | (53) | (30) |
| Net income to common shareholders | – | – | – | – | – | – | (53) | (30) |